Rebecca Frey
CIK: 0002145132
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
YARW
Yarrow Bioscience, Inc.
DirectorOfficer
Discretionary Trading P&L
Holdings
About Frey Rebecca
Frey Rebecca (SEC CIK 0002145132) files insider reports with the SEC as Chief Executive Officer of Yarrow Bioscience, Inc. (YARW).
Signal8 holds 2 ownership filings by Frey Rebecca (1 Form 3, 1 Form 4), filed between Jul 29, 2026 and Oct 30, 2026. Those filings report 1 transaction, the latest on Oct 29, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Frey Rebecca's filings is in NEW HAVEN, CT.
Recent filings by Frey Rebecca
- Oct 29, 2026: Grant or award of YARW derivative securities (Form 4, code A).
Other insiders filing for Yarrow Bioscience, Inc. (YARW)
- Payton Lori, Chief Development Officer
- Alford Rachael, Chief Operating Officer
- Ryder Steven, Chief Medical Officer
- Zeronda Tyler, Chief Financial Officer
- RTW Fund Group GP, LLC, 10% Owner
- Ashiya Mona, Director